>
Ascendis Pharma A/S logo

ASND - Ascendis Pharma A/S Share Price

$123.37 -2.2  -1.8%

Last Trade - 12/04/21

Sector
Healthcare
Size
Large Cap
Market Cap £4.93bn
Enterprise Value £4.38bn
Revenue £6.03m
Position in Universe 1170th / 6825
Bullish
Bearish
Unlock ASND Revenue
Momentum
Relative Strength (%)
1m -16.1%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -31.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
8.12 4.61 1.53 10.6 13.4 6.95 28.3 160.3 -3.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AscendisPharma A/S revenues decreased 48% to EUR7M. Net lossincreased 92% to EUR419M. Revenues reflect Revenue from therendering of services decrease of 78% to EUR2.1M, Licenseincome decrease of 2% to EUR2.6M. Higher net loss reflectsExchange rate losses increase from EUR0K to EUR78.9M(expense), Research and development costs - Balanceincrease of 59% to EUR156.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ASND
Graphical History

Revenue

ASND Revenue Unlock ASND Revenue

Net Income

ASND Net Income Unlock ASND Revenue

Normalised EPS

ASND Normalised EPS Unlock ASND Revenue

PE Ratio Range

ASND PE Ratio Range Unlock ASND Revenue

Dividend Yield Range

ASND Dividend Yield Range Unlock ASND Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ASND EPS Forecasts Unlock ASND Revenue
Profile Summary

ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated September 21, 2006
Public Since January 28, 2015
No. of Shareholders: 3
No. of Employees: 482
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 53,750,386
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ASND Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ASND
Upcoming Events for ASND
Frequently Asked Questions for Ascendis Pharma A/S
What is the Ascendis Pharma A/S share price?

As of 12/04/21, shares in Ascendis Pharma A/S are trading at $123.37, giving the company a market capitalisation of £4.93bn. This share price information is delayed by 15 minutes.

How has the Ascendis Pharma A/S share price performed this year?

Shares in Ascendis Pharma A/S are currently trading at $123.37 and the price has moved by 3.5% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Ascendis Pharma A/S price has moved by -30.24% over the past year.

What are the analyst and broker recommendations for Ascendis Pharma A/S?

Of the analysts with advisory recommendations for Ascendis Pharma A/S, there are there are currently 6 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Ascendis Pharma A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Ascendis Pharma A/S next release its financial results?

Ascendis Pharma A/S is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Ascendis Pharma A/S dividend yield?

Ascendis Pharma A/S does not currently pay a dividend.

Does Ascendis Pharma A/S pay a dividend?

Ascendis Pharma A/S does not currently pay a dividend.

When does Ascendis Pharma A/S next pay dividends?

Ascendis Pharma A/S does not currently pay a dividend.

How do I buy Ascendis Pharma A/S shares?

To buy shares in Ascendis Pharma A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Ascendis Pharma A/S?

Shares in Ascendis Pharma A/S are currently trading at $123.37, giving the company a market capitalisation of £4.93bn.

Where are Ascendis Pharma A/S shares listed? Where are Ascendis Pharma A/S shares listed?

Here are the trading details for Ascendis Pharma A/S:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ASND
What kind of share is Ascendis Pharma A/S?

Based on an overall assessment of its quality, value and momentum, Ascendis Pharma A/S is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Ascendis Pharma A/S share price forecast 2021?

Shares in Ascendis Pharma A/S are currently priced at $123.37. At that level they are trading at 56.73% discount to the analyst consensus target price of 0.00.

Analysts covering Ascendis Pharma A/S currently have a consensus Earnings Per Share (EPS) forecast of -7.289 for the next financial year.

How can I tell whether the Ascendis Pharma A/S share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ascendis Pharma A/S. Over the past six months, the relative strength of its shares against the market has been -32.59%. At the current price of $123.37, shares in Ascendis Pharma A/S are trading at -17.84% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Ascendis Pharma A/S PE Ratio?

We were not able to find PE ratio data for Ascendis Pharma A/S.

Who are the key directors of Ascendis Pharma A/S?

Ascendis Pharma A/S's management team is headed by:

Michael Jensen - CHM
Jan Moller Mikkelsen - PRE
Lotte Soenderbjerg - SVP
Albert Cha - IND
James Healy - IND
Flemming Jensen - SVP
Scott Smith - CFO
Jens Okkels - SVP
Lisa Bright - IND
Birgitte Volck - IND
Lars Holtug - IND
Vibeke Breinholt - SVP
Dana Pizzuti - SVP
Mark Bach - SVP
Jesper Hoiland - SVP
Who are the major shareholders of Ascendis Pharma A/S?

Here are the top five shareholders of Ascendis Pharma A/S based on the size of their shareholding:

T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 12.31% (6.62m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 10.91% (5.87m shares)
Artisan Partners Limited Partnership Investment Advisor
Percentage owned: 10.73% (5.77m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 9.23% (4.96m shares)
Baker Bros. Advisors LP Hedge Fund
Percentage owned: 6.59% (3.54m shares)
Similar to ASND
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.